Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891613 · ClinicalTrials.gov registry record · Phase 4
A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT05891613: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT05891613 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05891613, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.
Interventions
- DRUG Liposomal Bupivacaine
- DRUG Bupivacaine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2025-10-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05891613
The ClinicalTrials.gov registry entry for NCT05891613 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivacaine is the first listed.
NCT05891613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05891613 about?
NCT05891613 is a clinical study titled "A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction". The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.
What is the current status of trial NCT05891613?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2024-01-24. Estimated completion is 2025-10-06.
What interventions are being tested in trial NCT05891613?
The interventions under investigation include: Liposomal Bupivacaine (DRUG), Bupivacaine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05891613?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.